RBC raises Cytokinetics price target to $113, keeps Outperform
RBC Capital analyst Leonid Timashev raised Cytokinetics (CYTK) price target to $113 from $112 and maintained an Outperform rating, citing model adjustments and a Q3 biotech preview.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.